Search papers, labs, and topics across Lattice.
This paper describes the development of key performance indicators (KPIs) for the International Horizon Scanning Initiative (IHSI), which aims to facilitate decision-makers and payers in negotiating fair prices and preparing for potentially disruptive pharmaceuticals entering the European market. The study involved collaboration with IHSI member countries and its Executive Committee to develop KPIs related to database coverage, data timeliness, accuracy in identifying disruptive pharmaceuticals, and the use of High Impact Reports (HIRs). Accuracy of identifying disruptive pharmaceuticals was considered the most important KPI.
This study provides a framework of KPIs that can be used to evaluate and improve the effectiveness of international horizon scanning initiatives for pharmaceuticals, which could indirectly impact surgeons by influencing the availability and pricing of new orthopaedic drugs and biologics.
Abstract Introduction Many European countries independently conduct horizon scanning activities. However, the costs, time, and resources required can be prohibitive. To address this, the International Horizon Scanning Initiative (IHSI) was launched in 2019. IHSI aims to facilitate decision-makers and payers in negotiating fair prices and preparing for potentially disruptive pharmaceuticals. IHSI developed the Joint Horizon Scanning Database, a repository of pharmaceuticals expected to enter the European market, and initiated a series of High Impact Reports (HIRs) to highlight pharmaceuticals that have the potential to significantly impact healthcare systems. This paper outlines the development of key performance indicators (KPIs) that can be used to evaluate IHSI’s work. Results In close collaboration with representatives from IHSI member countries and its Executive Committee, the following KPIs were developed: “Number of IHSI member countries”, “Embedding of IHSI in national health technology assessment procedures”, “Database coverage”, “Data completeness”, “Data timeliness”, “Accuracy of identifying disruptive pharmaceuticals”, “Accuracy of identifying non-disruptive pharmaceuticals”, “Use of HIRs in preparing for disruption to the healthcare system”, and “Use of HIRs in price negotiations and financial arrangements”. Among these, “Accuracy of identifying disruptive pharmaceuticals” was considered most important, followed by “Data timeliness” and “Data completeness”. Additionally, based on consultations with nonmember countries, strategies for improvement were identified should the KPIs reveal areas for improvement. These include involving patients in the selection of pharmaceuticals and conducting reputation surveys alongside measuring KPIs. While the KPIs and strategies for improvement are specific to IHSI, they can be tailored to support other (international) horizon scanning initiatives.
